Participation notifications by The Goldman Sachs Group Press release Regulated information Brussels, February 12, 2026, 17:45 CET In line with Belgian transparency legislation (Law of May 2, 2007), The Goldman Sachs Group, Inc recently sent to Solvay the following transparency notifications. The Goldman Sachs Group, Inc was already above the 5% threshold since June 2025, with a total of 5.54%, of which 5.51% equivalent financial instruments. Here is a summary of the notifications: Date on which the threshold is crossed V...
Notifications de participation par The Goldman Sachs Group Communiqué de presse Information réglementée Bruxelles, le 12 février 2026 - 17h45 CET Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), The Goldman Sachs Group, Inc a envoyé récemment à Solvay les notifications de transparence suivantes. The Goldman Sachs Group, Inc était déjà au-dessus du seuil de 5% depuis juin 2025, avec un total de 5,54%, dont 5,51% en instruments financiers équivalents. Voici...
Participatiemeldingen van The Goldman Sachs Group Persbericht Gereglementeerde informatie Brussel, 12 februari 2026 - 17u45 CET In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft The Goldman Sachs Group, Inc onlangs de volgende transparantiekennisgevingen naar Solvay gestuurd. The Goldman Sachs Group, Inc had de drempel van 5% al overschreden in juni 2025 met een totaal van 5,54%, waarvan 5,51% aan stemrechten gelijkgestelde financiële instrumenten. Hier is een samenvatting van...
Company comments AB InBev: Little to disappoint Adyen: 2H25 results – mixed results, soft guidance CVC Capital Partners: Executing well dsm-firmenich: Messy results Fagron: Beat on all lines, confident FY26 outlook to drive c.5% consensus EBITDA upgrade Flow Traders: EMEA saves the day KBC: Good results, opening up “jaws” further to 2028 Kinepolis: Canadian peer Cineplex 4Q25 results below consensus, January 2026 box office revenue up MICC: FX headwind leads to a 50bp margin miss in FY25 Montea:...
4Q adj EBITDA for the continuing operations dropped by 4% y/y and was about 4% below our forecast and 3% below consensus. Dsm-firmenich's did not give FY26 guidance at this stage but promised to do so in the upcoming Investor Event (12 March). We remind that the long awaited and recently announced divestment of ANH disappointed on deal value (EV € 2.2bn, including a potential earn-out of up to € 0.5bn), but creates a group with a much more comprehensive activity and earnings profile. We still ap...
dsm-firmenich reports full year 2025 results Press ReleaseKaiseraugst (Switzerland), Maastricht (Netherlands), February 12, 2026 dsm-firmenich reports full year 2025 results Management Report 2025 highlights Good financial performance, with strong contribution from synergiesStrategic plan now fully executed following the announced divestment of Animal Nutrition & HealthAnimal Nutrition & Health has been classified as Assets Held for Sale and Discontinued OperationsNew €500 million share repurchase program to be launched in Q1 2026Maintain stable dividend of €2.50 per share, adopting st...
dsm-firmenich provides preliminary comparative figures following the announced divestment of Animal Nutrition & Health (ANH) Press Release dsm-firmenich provides preliminary comparative figures following the announced divestment of Animal Nutrition & Health (ANH) Kaiseraugst (Switzerland), Maastricht (Netherlands), February 9, 2026 Following the announced divestment of Animal Nutrition & Health (ANH) activities to CVC Capital Partners, the assets and liabilities of the divested business have been classified as Assets Held for Sale, and the financial results of the ANH activities have bee...
Dsm-firmenich announced the divestment of its ANH business to CVC, while it will retain a 20% minority stake for now. The deal value (EV of up to € 2.2bn for 100%; implying a c. 7x EV/normalized adjusted EBITDA multiple) is in line with recent market rumours although below our € 3bn forecast, while also other elements in the deal structure are a bit disappointing (price tag included €0.5bn earn-out, a loan & liquidity facility will be provided). Despite the lower than expected ANH deal metrics, ...
dsm-firmenich announces agreement to divest Animal Nutrition & Health to CVC Capital Partners Press Release dsm-firmenich announces agreement to divest Animal Nutrition & Health to CVC Capital Partners Kaiseraugst (Switzerland), Maastricht (Netherlands), February 9, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, today announces it has entered into an agreement with CVC, a leading global private markets manager, to divest its Animal Nutrition & Health (“ANH”) business for an enterprise value of about €2.2 billion, which includes an earnout of up to €0.5 billion. dsm-firm...
A director at Atenor SA bought 251,231 shares at 2.800EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.